<i>In vitro</i> and clinical data demonstrate negligible risk of drug–drug interactions with opelconazole, a novel inhaled antifungal agent
Systemic steady-state concentrations achieved after clinical dosing of inhaled opelconazole are unlikely to be associated with CYP-mediated DDIs or transporter-mediated DDIs.
Authors
- Lance Berman
- John Ayrton
- Jerome A. Moore
- Michele Hyman
- Roger J. M. Brüggemann (ORCID: https://orcid.org/0000-0002-7618-725X)
- Lindsey Cass (ORCID: https://orcid.org/0000-0003-3719-0883)
- Ubaldo J. Martin (ORCID: https://orcid.org/0000-0002-0089-7677)
- Laura Grey
Institutions
- ECRI Institute (US)
- Bentley University (US)
- Radboud University Nijmegen (NL)
- Zimmer Biomet (Netherlands) (NL)
- Pacific Environment (US)
- Radboud University Medical Center (NL)
- Essex Cardiothoracic Centre (GB)
- Pacific Southwest Research Station (US)
- TE Laboratories (Ireland) (IE)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1093/jac/dkaf384
- Citations
- 3
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 4.19